Search Articles

View query in Help articles search

Search Results (1 to 1 of 1 Results)

Download search results: CSV END BibTex RIS


Mortality Risk Prediction in Patients With Antimelanoma Differentiation–Associated, Gene 5 Antibody–Positive, Dermatomyositis–Associated Interstitial Lung Disease: Algorithm Development and Validation

Mortality Risk Prediction in Patients With Antimelanoma Differentiation–Associated, Gene 5 Antibody–Positive, Dermatomyositis–Associated Interstitial Lung Disease: Algorithm Development and Validation

Dermatomyositis (DM), which predominantly affects the skin and muscles, is a prevalent subtype within the IIM spectrum. Interstitial lung disease (ILD) is a common comorbidity in DM, with an incidence varying widely from 5% to 65% [1]. The clinical presentations, treatment responses, and outcomes of IIMs are highly variable and correlate with the presence of specific myositis-specific antibodies (MSAs).

Hui Li, Ruyi Zou, Hongxia Xin, Ping He, Bin Xi, Yaqiong Tian, Qi Zhao, Xin Yan, Xiaohua Qiu, Yujuan Gao, Yin Liu, Min Cao, Bi Chen, Qian Han, Juan Chen, Guochun Wang, Hourong Cai

J Med Internet Res 2025;27:e62836